Cargando…

A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients

Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients. To investigate the efficacy of ETV in Chinese nucleos(t)ide(NA)-experienced CHB patients. Among 89 CHB patients with ETV monotherapy for ≥6 months, 33/89 (37%) or 56/89 (73%) were NA-naïve or NA-experienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Kehui, Xiang, Xiaogang, Bao, Rebecca, Chen, Rong, Liu, Yunye, Xie, Jingdong, Guo, Qing, Bao, Shisan, Xie, Qing, Wang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929461/ https://www.ncbi.nlm.nih.gov/pubmed/27364728 http://dx.doi.org/10.1038/srep28779

Ejemplares similares

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma
por: Liu, Kehui, et al.
Publicado: (2022)

Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure
por: Cao, Zhujun, et al.
Publicado: (2015)

Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
por: Chen, Lu, et al.
Publicado: (2020)

Erratum to: Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
por: Chen, Lu, et al.
Publicado: (2021)

Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B
por: Cao, Lihua, et al.
Publicado: (2023)

Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome
por: Chen, Liwen, et al.
Publicado: (2020)

Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients
por: Chen, Liwen, et al.
Publicado: (2018)

AL amyloidosis with primary presentation of multiple serous cavity effusion and severe cholestasis: a case report and review of literature
por: Liu, Kehui, et al.
Publicado: (2022)

Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B
por: Jin, Xi, et al.
Publicado: (2012)

Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis
por: Gui, Hong-Lian, et al.
Publicado: (2020)

240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C
por: Xu, Jing‐Hang, et al.
Publicado: (2022)

Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV‐related hepatocellular carcinoma
por: Ding, Yezhou, et al.
Publicado: (2020)

Clinical utility of entecavir for chronic hepatitis B in Chinese patients
por: Wang, Jiyao
Publicado: (2013)

The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B
por: Tang, Hong, et al.
Publicado: (2013)

Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone
por: Oh, Myung Jin, et al.
Publicado: (2016)

Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
por: Li, Jun, et al.
Publicado: (2023)

One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C
por: Xu, Jing-Hang, et al.
Publicado: (2022)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening
por: Wang, Hui, et al.
Publicado: (2015)

Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study
por: Du, Qing-Wei, et al.
Publicado: (2013)

An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir
por: Liu, Yi-Qi, et al.
Publicado: (2023)

SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease
por: Liu, Yuhan, et al.
Publicado: (2016)

Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants
por: Li, Ping, et al.
Publicado: (2017)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
por: Hwang, Joo An, et al.
Publicado: (2015)

The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
por: Ding, Yezhou, et al.
Publicado: (2023)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy
por: Yuan, Chunyan, et al.
Publicado: (2022)

Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B
por: Korolowicz, Kyle E., et al.
Publicado: (2021)

Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy
por: Zhang, Xia-Xia, et al.
Publicado: (2016)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients
por: You, Jing, et al.
Publicado: (2008)

Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy
por: Wang, Yun, et al.
Publicado: (2016)

Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients
por: Xie, Yan-Di, et al.
Publicado: (2017)

Safety and efficacy of entecavir for the treatment of chronic hepatitis B
por: Osborn, Melissa
Publicado: (2011)

Dupilumab in patients with chronic hepatitis B on concomitant entecavir
por: Ly, Karen, et al.
Publicado: (2019)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
por: Ahn, Sang Hoon, et al.
Publicado: (2013)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog
por: Jiang, Lei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o8enigdtv5dt7reqp9f3s2lqmo